News

According to the agreement, Xilio Therapeutics may periodically offer and sell company common stock with a total value of up to $17.22 million through an "at-the-market" offering method. Leerink Partners will serve as the sales agent, responsible for the stock offering. This type of financing arrangement provides the company with a flexible capital-raising channel, enabling it to sell shares on the open market in a timely manner based on market conditions and its own funding needs to obtain operating funds. The potential proceeds from this offering will be used for general corporate purposes, which may include advancing the research and development of its tumor immunotherapy pipeline, clinical trials, and other operational expenses.

Ofgem stated in a declaration on Tuesday that it has approved early funding for transmission lines and upgrade works for certain transmission projects in Scotland, bringing the number of fast-tracked grid projects to 26. Companies will be able to secure key materials in advance, such as heavy-duty cables and substation equipment, which are currently impacted by global supply bottlenecks that could delay project progress.

Odaily reported that Michael Saylor posted on X, stating that last night's CLARITY Act review will unleash the next wave of digital capital, digital credit, and digital equity in the United States and globally, provide institutional validation for BTC, offer a framework for the digital yield market driven by STRC, and promote broader adoption of MSTR.